Please login to the form below

Not currently logged in
Email:
Password:

Lartruvo

This page shows the latest Lartruvo news and features for those working in and with pharma, biotech and healthcare.

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Authorisation revoked for Lartruvo. Friday’s ruling was also notable for the CHMP’s decision to revoke the marketing authorisation for Eli Lilly’s sarcoma treatment Lartruvo, after the drug failed

Latest news

  • Lilly to withdraw Lartruvo, a first for accelerated approval failures Lilly to withdraw Lartruvo, a first for accelerated approval failures

    Existing patients can use access programme. Eli Lilly is to withdraw its soft tissue sarcoma treatment Lartruvo from the market after it failed a post-marketing efficacy study. ... The trial studied Lartruvo combined with standard treatment doxorubicin,

  • EMA says Lilly’s Lartruvo should not be prescribed EMA says Lilly’s Lartruvo should not be prescribed

    Lilly said at the time it would stop promoting Lartruvo and would book a $70m-$90m charge this quarter as a result. ... Meanwhile, the trial failure also impacts Lartruvo in the US, as the FDA also approved the drug early on the promise of follow-up data.

  • Lilly bags EU approval for cancer treatment Lartruvo Lilly bags EU approval for cancer treatment Lartruvo

    Licensed for use with doxorubicin for soft tissue sarcoma patients. The European Commission has granted Lilly's Lartruvo (orlaratumab) marketing authorisation for the first-line treatment of patients with advanced soft ... Until then, Lartruvo will be

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Eli Lilly has picked up its first green light for its soft tissue sarcoma (STS) therapy Lartruvo, ending a four-decade drought for new front-line therapies. ... The US FDA granted accelerated approval to Lartruvo (olaratumab) used in combination with

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    Eli Lilly could be just weeks away from EU approval of its advanced soft tissue sarcoma (STS) treatment Lartruvo after a positive recommendation from the Committee for Medicinal Products for Human ... It is thought that by binding to the receptor

More from news
Approximately 6 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...
OPEN Health use PR to support clinical trial recruitment
International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
Covid-19: what could it mean for the diabetic population?
Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...

Infographics